• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Physiological and pathological functions of TNF/TNF receptor family molecules.

Research Project

Project/Area Number 14370117
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Immunology
Research InstitutionJuntendo University

Principal Investigator

YAGITA Hideo  Juntendo University, School of Medicine, Associate Professor, 医学部, 助教授 (30182306)

Project Period (FY) 2002 – 2004
Project Status Completed (Fiscal Year 2004)
Budget Amount *help
¥13,500,000 (Direct Cost: ¥13,500,000)
Fiscal Year 2004: ¥4,400,000 (Direct Cost: ¥4,400,000)
Fiscal Year 2003: ¥4,400,000 (Direct Cost: ¥4,400,000)
Fiscal Year 2002: ¥4,700,000 (Direct Cost: ¥4,700,000)
KeywordsFasL / Fas / TRAIL / DR5 / TWEAK / Fn14 / OX4OL / 0X40 / 4-1BBL / 4-1BB / CD70 / CD27 / CD30L / CD30 / TRANCE / RANK / TNF / 腫瘍免疫 / 移植 / 自己免疫 / GVHD / 細胞死
Research Abstract

(1)We have identified a novel transcriptional activator named BSAC, which suppresses TNF-induced cell death. We have also revealed that TRAF-mediated NF-κB activation suppresses TNF-induced ROS accumulation, which leads to prolonged JNK activation and necrotic cell death.
(2)We have revealed that FasL mediates immunosuppression induced by high-dose antigen administration or T. cruzi infection. We have also revealed the involvement of FasL in pathogenesis of colitis and pneumonia. Moreover, we have identified monkey FasL and established its detection system.
(3)We have revealed critical role for TRAIL in immune surveillance against tumor development and metastasis, and GVT effect after BMT. We have also demonstrated that blockade of NF-κB activation can sensitize various tumor cells to TRAIL-induced apoptosis. Moreover, we have found that TRAIL can act immunosuppressive by inducing apoptosis in immature dendritic cells and plasma cells.
(4)We have found that agonistic mAb against death-ind … More ucing mouse TRAIL receptor (DR5) can not only induce regression of TRAIL-sensitive tumors transiently but also induce tumor-specific CTL, which can also eradicate TRAIL-resistant variants, via recruitment of host antigen-presenting cells by its Fc portion.
(5)We have revealed that a new member of TNF receptor family, Fn14, can mediate TWEAK-induced cell death. We have also found pro-inflammatory function of TWEAK/Fn14 against endothelial and epithelial cells. Moreover, we have characterized the expression and function of mouse TWEAK/Fn14 by using newly generated mAbs.
(6)We have found that CD27-mediated NK cell activation by CD70 on tumor cells can induce tumor-specific T cell responses in IFN-γ-dependent manner. We have also revealed that CD70 plays critical role in CD4 T cell-independent CTL induction by activated dendrific cells and in CD28-independent cardiac allograft rejection by CD8 T cells.
(7)We have found that OX40L plays critical role in allograft rejection and pathogenesis of GVHD, colotis, and asthma.
(8)We have characterized the expression and function of mouse 4-1BBL by using newly generated mAbs.
(9)We have revealed critical role of CD30L in pathogenesis of CD4 T cell-mediated GVHD and protective immunity to M.avium.
(10)We have characterized the expression and function of mouse TRANCE/RANK by using newly generated mAbs. We have also found potent activity of TRANCE-expressing plasmid as a genetic adjuvant. Less

Report

(4 results)
  • 2004 Annual Research Report   Final Research Report Summary
  • 2003 Annual Research Report
  • 2002 Annual Research Report
  • Research Products

    (40 results)

All 2004 2003 2002 Other

All Journal Article (16 results) Publications (24 results)

  • [Journal Article] Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.2004

    • Author(s)
      Takeda, K.
    • Journal Title

      J.Exp.Med. 199

      Pages: 437-448

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Annual Research Report 2004 Final Research Report Summary
  • [Journal Article] Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression.2004

    • Author(s)
      Luo, J.
    • Journal Title

      Cancer Cell 6

      Pages: 297-305

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Annual Research Report 2004 Final Research Report Summary
  • [Journal Article] Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.2004

    • Author(s)
      Takeda, K. et al.
    • Journal Title

      J.Exp.Med. 199

      Pages: 437-448

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression.2004

    • Author(s)
      Luo, J.et al.
    • Journal Title

      Cancer Cell 6

      Pages: 297-305

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy.2004

    • Author(s)
      Hayakawa, Y.
    • Journal Title

      J.Immunol. 172

      Pages: 123-129

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Critical role of OX40 in CD28 and CD154-independent rejection.2004

    • Author(s)
      Demirci, G.
    • Journal Title

      J.Immunol. 172

      Pages: 1691-1698

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.2004

    • Author(s)
      Hasegawa, A.
    • Journal Title

      Proc.Natl.Acad.Sci.USA 101

      Pages: 6599-6604

    • Related Report
      2004 Annual Research Report
  • [Journal Article] T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis.2004

    • Author(s)
      Hao, Z.
    • Journal Title

      J.Exp.Med. 199

      Pages: 1355-1365

    • Related Report
      2004 Annual Research Report
  • [Journal Article] OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation.2003

    • Author(s)
      Salek-Ardakani, S.
    • Journal Title

      J.Exp.Med. 198

      Pages: 315-324

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation.2003

    • Author(s)
      Salek-Ardakani, S. et al.
    • Journal Title

      J.Exp.Med. 198

      Pages: 315-324

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.2002

    • Author(s)
      Kelly, J.M.
    • Journal Title

      Nature Immunol. 3

      Pages: 83-90

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.2002

    • Author(s)
      Takeda, K.
    • Journal Title

      J.Exp.Med. 195

      Pages: 161-169

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] T cells require TRAIL for optimal graft-versus-tumor activity.2002

    • Author(s)
      Schmaltz, C.
    • Journal Title

      Nature Med. 8

      Pages: 1433-1437

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.2002

    • Author(s)
      Kelly, J.M.et al.
    • Journal Title

      Nature Immunol. 3

      Pages: 83-90

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Critical role for TRAIL in immune surveillance against tumor development.2002

    • Author(s)
      Takeda, K. et al.
    • Journal Title

      J.Exp.Med. 195

      Pages: 171-179

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] T cells require TRAIL for optimal graft-versus-tumor activity.2002

    • Author(s)
      Schmaltz, C. et al.
    • Journal Title

      Nature Med. 8

      Pages: 1433-1437

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Publications] Seki, N.: "TRAIL-mediated apoptosis is an important endogeneous mechanism ofrresistance to liver metastases in murine renal cancer."Cancer Res. 63. 207-213 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Miura, Y.: "TRAIL induces neuronal death in a murine model of HIV central nervous system infection."Proc.Natl.Acad.Sci.USA. 100. 2777-2782 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kirii, Y.: "Molecular cloning, functional characterization, and enzyme-linked immunosolbent assay of cynomolgus monkey Fas ligand."J.Immunol.Methods. 278. 201-209 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Dan, N.: "Amelirating effect of anti-Fas ligand mAb on wasting disease in murine model of chronic colitis."Am.J.Physiol.Gastrointest.Liver Physiol.. 285. 754-760 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Nakayama, M.: "Fn14 mediates multiple pathways of TWEAK-induced cell death."J.Immunol.. 170. 341-348 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Nakayama, M.: "Chracterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies."Biochem.Bioph.Res.Comm.. 306. 819-825 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Blazar, B.R.: "Ligation of 0X40(CD134) regulates grafi-versus-host disease(GVHD) and graft rejection in allogeneic done marrow transplant (BMT) recipients."Blood. 101. 3741-3748 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Yuan, X.: "Role of CD134-CD134 ligand costimulatory pathway in atloimmune response in vivo."J.Immunol. 170. 2949-2955 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Hoshino, A.: "Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma."Eur.J.Immunol. 33. 861-869 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Totsuka, T.: "Therapeutic effect of anti-OX40L and anti-TNF mAbs in a murine model of chronic colitis."Am.J.Physiol-Gastrointest. Liver Physiol. 284. 595-603 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Chakrabarty, S.: "Critical roles of CD30/CD30L interaction in murine autoimmune diabetes."Clin.Exp. Immunol.. 133. 318-325 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Miyahira, Y.: "A potent adjuvant effect of RANK ligand gene for inducing antigen-specific CD8+T cell response by DNA and viral vector vaccination"J.Immunol. 171. 6344-6348 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Seki, N.: "Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogeneous mechanism for resistance to liver metastases in murine renalcancer"Cancer Res.. 63. 207-213 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Takeda, K.: "Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development"J.Exp.Med.. 195. 171-179 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Schmaltz, C.: "T cells require TRAIL for optimal graft-versus-tumor activity"Nature Med.. 8. 1433-1437 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Ursini-Siegel, J.: "TRAIL/Apo-2 ligand induces primary plasma cell apoptosis"J.Immunol.. 169. 5505-5513 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakayama, M.: "Multiple pathways of TWEAK-induced cell death"J.Immunol.. 168. 734-743 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakayama, M.: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death"J.Immunol.. 170. 341-348 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Harada, N.: "Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells"Biochem.Bioph.Res.Comm.. 299. 488-493 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakayama, M.: "Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes"Diabetes. 51. 1391-1397 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kelly, J.M.: "Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection"Nature Immunol.. 3. 83-90 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Futagawa, T.: "Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells"Int.Immunol.. 14. 275-286 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Tian, L.: "Association of the CD134/CD134L constimulatory pathway with acute rejection of small bowel allograft"Transplantation. 74. 133-138 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Blazar, B.R.: "Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allageneic bone marrow transplant (BMT) recipients"Blood. (in press). (2003)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi